M&R Capital Management Inc. continued to hold its position in SPDR S&P Biotech (NYSEARCA:XBI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,690 shares of the exchange traded fund’s stock at the close of the 2nd quarter. M&R Capital Management Inc.’s holdings in SPDR S&P Biotech were worth $582,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of SPDR S&P Biotech by 13.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 240,709 shares of the exchange traded fund’s stock valued at $18,578,000 after purchasing an additional 29,346 shares during the last quarter. Laurel Wealth Advisors Inc. bought a new stake in shares of SPDR S&P Biotech in the 2nd quarter valued at $1,198,000. Private Advisory Group LLC boosted its stake in shares of SPDR S&P Biotech by 52.0% in the 2nd quarter. Private Advisory Group LLC now owns 10,013 shares of the exchange traded fund’s stock valued at $773,000 after purchasing an additional 3,424 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of SPDR S&P Biotech by 3,464.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 7,129 shares of the exchange traded fund’s stock valued at $550,000 after purchasing an additional 6,929 shares during the last quarter. Finally, NBW Capital LLC bought a new stake in shares of SPDR S&P Biotech in the 2nd quarter valued at $3,810,000.

TRADEMARK VIOLATION WARNING: “M&R Capital Management Inc. Has $582,000 Holdings in SPDR S&P Biotech (XBI)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/09/mr-capital-management-inc-has-582000-holdings-in-spdr-sp-biotech-xbi.html.

SPDR S&P Biotech (NYSEARCA XBI) traded down 0.6243% during midday trading on Monday, hitting $87.7686. 849,916 shares of the stock were exchanged. The company’s 50 day moving average is $83.21 and its 200-day moving average is $75.57. SPDR S&P Biotech has a 1-year low of $53.15 and a 1-year high of $88.98.

The business also recently declared a quarterly dividend, which was paid on Monday, September 25th. Investors of record on Monday, September 18th were issued a $0.037 dividend. This represents a $0.15 annualized dividend and a yield of 0.17%. The ex-dividend date of this dividend was Friday, September 15th.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Stock Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related stocks with our FREE daily email newsletter.